Patents by Inventor Fredrik Zetterberg

Fredrik Zetterberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Alpha-D-galactoside inhibitors of galectins
    Patent number: 10889610
    Abstract: The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: July 9, 2017
    Date of Patent: January 12, 2021
    Assignee: GALECTO BIOTECH AB
    Inventors: Fredrik Zetterberg, Ulf Nilsson, Hakon Leffler
  • NOVEL GALACTOSIDE INHIBITOR OF GALECTINS
    Publication number: 20200407391
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: September 11, 2020
    Publication date: December 31, 2020
    Applicant: Galecto Biotech AB
    Inventors: Thomas BRIMERT, Richard JOHNSSON, Hakon LEFFLER, Ulf NILSSON, Fredrik ZETTERBERG
  • NOVEL GALACTOSIDE INHIBITOR OF GALECTINS
    Publication number: 20200347089
    Abstract: An ?-D-galactopyranose compound of the general formula (1). The ?-D-galactopyranose compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human. Furthermore, a method for treatment of a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: January 9, 2019
    Publication date: November 5, 2020
    Applicant: GALECTO BIOTECH AB
    Inventor: Fredrik ZETTERBERG
  • Hybrid galactoside inhibitor of galectins
    Patent number: 10800804
    Abstract: Provided is a compound of the general formula (1), which is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human, as well as a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: October 13, 2020
    Inventors: Hakon Leffler, Ulf Nilsson, Fredrik Zetterberg
  • Galactoside inhibitor of galectins
    Patent number: 10774102
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: September 15, 2020
    Assignee: Galecto Biotech AB
    Inventors: Thomas Brimert, Richard Johnsson, Hakon Leffler, Ulf Nilsson, Fredrik Zetterberg
  • 1,1 ?-sulfanediyl-di-beta-D-galactopyranosides as inhibitors of galectins
    Patent number: 10730902
    Abstract: The present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: August 4, 2020
    Assignee: GALECTO BIOTECH AB
    Inventors: Fredrik Zetterberg, Ulf Nilsson, Hakon Leffler, Anders Pedersen, Hans Schambye, Thomas Brimert, Richard Johnsson
  • NOVEL HYBRID GALACTOSIDE INHIBITOR OF GALECTINS
    Publication number: 20200115410
    Abstract: Provided is a compound of the general formula (1), which is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human, as well as a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: November 26, 2018
    Publication date: April 16, 2020
    Inventors: Hakon LEFFLER, Ulf NILSSON, Fredrik ZETTERBERG
  • Galactoside inhibitor of galectins
    Patent number: 10526360
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: January 7, 2020
    Assignee: Galecto Biotech AB
    Inventors: Thomas Brimert, Richard Johnsson, Hakon Leffler, Ulf Nilsson, Fredrik Zetterberg
  • NOVEL GALACTOSIDE INHIBITOR OF GALECTINS
    Publication number: 20190359643
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: August 13, 2019
    Publication date: November 28, 2019
    Applicant: Galecto Biotech AB
    Inventors: Thomas BRIMERT, Richard JOHNSSON, Hakon LEFFLER, Ulf NILSSON, Fredrik ZETTERBERG
  • Galactoside inhibitor of galectins
    Patent number: 10464964
    Abstract: An Embodiment of the invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: November 5, 2019
    Assignee: Galecto Biotech AB
    Inventors: Fredrik Zetterberg, Ulf Nilsson, Hakon Leffler, Thomas Brimert, Richard Johnsson, Priya Verma
  • ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS
    Publication number: 20190315793
    Abstract: The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: July 9, 2017
    Publication date: October 17, 2019
    Applicant: GALECTO BIOTECH AB
    Inventors: Fredrik ZETTERBERG, Ulf NILSSON, Hakon LEFFLER
  • ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS
    Publication number: 20190225638
    Abstract: The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: July 9, 2017
    Publication date: July 25, 2019
    Applicant: GALECTO BIOTECH AB
    Inventors: Fredrik ZETTERBERG, Hakon LEFFLER, Ulf NILSSON
  • Hybrid galactoside inhibitor of galectins
    Patent number: 10253059
    Abstract: The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: April 9, 2019
    Assignee: GALECTO BIOTECH AB
    Inventors: Hakon Leffler, Ulf Nilsson, Fredrik Zetterberg
  • NOVEL GALACTOSIDE INHIBITORS OF GALECTINS
    Publication number: 20180327440
    Abstract: The present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: November 8, 2016
    Publication date: November 15, 2018
    Applicant: GALECTO BIOTECH AB
    Inventors: Fredrik ZETTERBERG, Ulf NILSSON, Hakon LEFFLER, Anders PEDERSEN, Hans SCHAMBYE, Thomas BRIMERT, Richard JOHNSSON
  • ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS
    Publication number: 20170349619
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: January 28, 2016
    Publication date: December 7, 2017
    Applicant: Galecto Biotech AB
    Inventors: Thomas BRIMERT, Richard JOHNSSON, Hakon LEFFLER, Ulf NILSSON, Fredrik ZETTERBERG
  • NOVEL HYBRID GALACTOSIDE INHIBITOR OF GALECTINS
    Publication number: 20170349622
    Abstract: The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: July 6, 2015
    Publication date: December 7, 2017
    Applicant: GALECTO BIOTECH AB
    Inventors: Hakon LEFFLER, Ulf NILSSON, Fredrik ZETTERBERG
  • NOVEL GALACTOSIDE INHIBITOR OF GALECTINS
    Publication number: 20170334940
    Abstract: An Embodiment of the invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: January 14, 2016
    Publication date: November 23, 2017
    Applicant: Galecto Biotech AB
    Inventors: Fredrik ZETTERBERG, Ulf NILSSON, Hakon LEFFLER, Thomas BRIMERT, Richard JOHNSSON, Priya VERMA
  • New Pyridine Analogues V
    Publication number: 20110059981
    Abstract: The present invention relates to certain new pyridin analogues of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
    Type: Application
    Filed: July 2, 2007
    Publication date: March 10, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Kay Brickmann, Fabrizio Giordanetto, Johan Johansson, Fredrik Zetterberg
  • New Pyridine Analogues V
    Publication number: 20090318464
    Abstract: The present invention relates to certain new pyridin analogues of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
    Type: Application
    Filed: July 2, 2007
    Publication date: December 24, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Kay Brickmann, Fabrizio Giordanetto, Johan Johansson, Fredrik Zetterberg
  • Novel Pyridine Compounds
    Publication number: 20090227555
    Abstract: The present invention relates to certain novel pyridin compounds of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-thrombotic agents etc, and processes for their preparation, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
    Type: Application
    Filed: June 23, 2008
    Publication date: September 10, 2009
    Applicant: AstraZeneca AB
    Inventors: Peter Bach, Jonas Bostrom, Kay Brickmann, Leifeng Cheng, Fabrizio Giordanetto, Robert Groneberg, Darren Harvey, Michael O'Sullivan, Fredrik Zetterberg